Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (1,181)	$ (1,544)
Adjustments to reconcile net loss to net cash used in operating activities
Gain on sales of in process research and development	(139)	(445)
Accretion on short-term investments	(298)
Stock-based compensation expense	160	71
Changes in operating assets and liabilities:
Prepaid expenses and other assets	80	91
Accounts payable, accrued expenses and other	(148)	27
Other assets	4	58
Net cash used in operating activities	(1,522)	(1,742)
Cash flows from investing activities
Proceeds from sale of in-process research and development assets	139	445
Proceeds from maturity of short-term investments	6,000
Purchases of short-term investments	(18,588)
Net cash (used in) provided by investing activities	(12,449)	445
Cash flows from financing activities
Proceeds from exercise of options	521	6,533
Net cash provided by financing activities	521	6,533
Net (decrease) increase in cash and cash equivalents	(13,450)	5,236
Cash and cash equivalents, beginning of year	19,439	14,203
Cash and cash equivalents, end of year	$ 5,989	$ 19,439